Hemispherx acquires patent estate from Vanderbilt to create new vaccine technology platform

By Lisa Kerner

Charlotte, N.C., Aug. 29 - Hemispherx Biopharma, Inc. said it acquired worldwide exclusive licensure of the international patent estate developed at Vanderbilt University for the in vivo use of the chemical compound DOGS (dioctadecylamidoglycylspermine) for the delivery of therapeutic DNA to the interior of cells.

Using DOGS technology increases the effectiveness of DNA technology by more than 100 fold.

The company plans to combine the DOGS delivery of genetic immunogens with its own immunostimulatory drug, Ampligen, to create a new vaccine technology platform, Vaccine Enhance.

Hemispherx said this acquisition provides an enabling mechanism for genetic (DNA) vaccination, an important element in the U.S. Department of Health and Human Services' biodefense program.

Philadelphia-based Hemispherx develops new drug entities for treatment of viral and immune-based disorders, including gene-based disdorders such as Chronic Fatigue Syndrome.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.